Isolated limb perfusion with high-dose tumor necrosis factor-alpha for locally advanced extremity soft tissue sarcomas.
Eggermont
A M
AM
Department of Surgery, Rotterdam Cancer Institute (Dr. Daniel den Hoed Kliniek, The Netherlands.
Schraffordt Koops
H
H
Klausner
J M
JM
Schlag
P M
PM
Kroon
B B
BB
Ben-Ari
G
G
Lejeune
F J
FJ
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005121:Extremities; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012509:Sarcoma / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D012983:Soft Tissue Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D015996:Survival Rate; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000009:adverse effects / Q000627:therapeutic use*
D014409:Tumor Necrosis Factor-alpha